In the CHX chase assay, tunicamycin led to degradation inhibition (Fig. 8E) and a longer half-life of PTGDS (Fig. 8F) in DLBCL, which might partly explain the discrepancy between PTGDS protein and mRNA expression level. The gene discussed is PTGDS; the disease is diffuse large B-cell lymphoma.